Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIB-IMRT with modulated accelerated fractionation plus Cetuximab for head and neck cancer
2012-002765-36Phase 4Completed
- Sponsor
- European Institute of Oncology
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by European Institute of Oncology. Primary endpoint: Feasibility of time-dose modulated SIB-IMRT in clinical practice. Started Jan 2014; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2012-002765-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002765-36.